

## DESCRIPTION

<b>Species Reactivity</b>	Human
<b>Specificity</b>	Detects human CXCL13/BLC/BCA-1 in ELISAs and Western blots. In ELISAs, no cross-reactivity with recombinant human (rh) CXCL1, rhCXCL2, rhCXCL3, rhCXCL8/IL-8, rhCXCL10, rhCXCL9, rhCXCL12/SDF-1 $\alpha$ , or rhCXCL12/SDF-1 $\beta$ is observed. In Western blots, no cross-reactivity with recombinant mouse CXCL13/BLC/BCA-1 is observed.
<b>Source</b>	Monoclonal Mouse IgG <sub>1</sub> Clone # 53610
<b>Purification</b>	Protein A or G purified from hybridoma culture supernatant
<b>Immunogen</b>	<i>E. coli</i> -derived recombinant human CXCL13/BLC/BCA-1 Val23-Arg94 Accession # O43927
<b>Endotoxin Level</b>	<0.10 EU per 1 $\mu$ g of the antibody by the LAL method.
<b>Formulation</b>	Lyophilized from a 0.2 $\mu$ m filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied as a 0.2 $\mu$ m filtered solution in PBS.


## APPLICATIONS

**Please Note:** Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the *Technical Information* section on our website.

	Recommended Concentration	Sample
<b>Western Blot</b>	1 $\mu$ g/mL	See Below
<b>Intracellular Staining by Flow Cytometry</b>	2.5 $\mu$ g/10 <sup>6</sup> cells	Human monocyte-derived immature dendritic cells fixed with paraformaldehyde and permeabilized with saponin
<b>Human CXCL13/BLC/BCA-1 Sandwich Immunoassay</b>		<b>Reagent</b>
<b>ELISA Capture</b>	2-8 $\mu$ g/mL	Human CXCL13/BLC/BCA-1 Antibody (Catalog # MAB801)
<b>ELISA Detection Standard</b>	0.1-0.4 $\mu$ g/mL	Human CXCL13/BLC/BCA-1 Biotinylated Antibody (Catalog # BAF801) Recombinant Human CXCL13/BLC/BCA-1 (Catalog # 801-CX)
<b>CyTOF-ready</b>	Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.	
<b>Neutralization</b>	Measured by its ability to neutralize CXCL13/BLC/BCA-1-induced chemotaxis in the BaF3 mouse pro-B cell line transfected with human CXCR5. The Neutralization Dose (ND <sub>50</sub> ) is typically 0.3-0.9 $\mu$ g/mL in the presence of 0.05 $\mu$ g/mL Recombinant Human CXCL13/BLC/BCA-1.	


## DATA

### Western Blot



**Detection of Recombinant Human CXCL13/BLC/BCA-1 by Western Blot.** Western blot shows 100 ng of Recombinant Human CXCL13/BLC/BCA-1 (Catalog # 801-CX) and Recombinant Mouse CXCL13/BLC/BCA-1 (Catalog # 470-BC). PVDF Membrane was probed with 1  $\mu$ g/mL of Mouse Anti-Human CXCL13/BLC/BCA-1 Monoclonal Antibody (Catalog # MAB801) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF007). A specific band was detected for CXCL13/BLC/BCA-1 at approximately 12 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 3.

### Neutralization



**Chemotaxis Induced by CXCL13/BLC/BCA-1 and Neutralization by Human CXCL13/BLC/BCA-1 Antibody.** Recombinant Human CXCL13/BLC/BCA-1 (Catalog # 801-CX) chemoattracts the BaF3 mouse pro-B cell line transfected with human CXCR5 in a dose-dependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin (Catalog # AR002). Chemotaxis elicited by Recombinant Mouse Anti-Human CXCL13/BLC/BCA-1 (0.05  $\mu$ g/mL) is neutralized (green line) by increasing concentrations of Human CXCL13/BLC/BCA-1 Monoclonal Antibody (Catalog # MAB801). The ND<sub>50</sub> is typically 0.3-0.9  $\mu$ g/mL.

## PREPARATION AND STORAGE

<b>Reconstitution</b>	Reconstitute at 0.5 mg/mL in sterile PBS.
<b>Shipping</b>	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
<b>Stability &amp; Storage</b>	<b>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.</b> <ul style="list-style-type: none"> <li>• 12 months from date of receipt, -20 to -70 °C as supplied.</li> <li>• 1 month, 2 to 8 °C under sterile conditions after reconstitution.</li> <li>• 6 months, -20 to -70 °C under sterile conditions after reconstitution.</li> </ul>

## BACKGROUND

CXCL13, also known as B-lymphocyte chemoattractant (BLC), is a CXC chemokine that is constitutively expressed in secondary lymphoid organs. BCA-1 cDNA encodes a protein of 109 amino acid residues with a leader sequence of 22 residues. Mature human BCA-1 shares 64% amino acid sequence similarity with the mouse protein and 23-34% amino acid sequence identity with other known CXC chemokines. Recombinant or chemically synthesized BCA-1 is a potent chemoattractant for B lymphocytes but not T lymphocytes, monocytes or neutrophils. BLR1, a G protein-coupled receptor originally isolated from Burkitt's lymphoma cells, has now been shown to be the specific receptor for BCA-1. Among cells of the hematopoietic lineages, the expression of BLR1, now designated CXCR5, is restricted to B lymphocytes and a subpopulation of T helper memory cells. Mice lacking BLR1 have been shown to lack inguinal lymph nodes. These mice were also found to have impaired development of Peyer's patches and defective formation of primary follicles and germinal centers in the spleen as a result of the inability of B lymphocytes to migrate into B cell areas.

## References:

1. Gunn, M.D. *et al.* (1998) *Nature*, **391**:799.
2. Legler, D.F. *et al.* (1998) *J. Exp. Med.* **187**:655.
3. Forster, R. *et al.* (1996) *Cell* **87**:1037.